UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Response of dosemeters in the radiation field generated by a TW-class laser system

Radiation protection dosimetry, 2014-10, Vol.161 (1-4), p.343-346

2014

Volltextzugriff (PDF)

Semiconductor and Thermoluminescent Dosimetry of Pulsed Soft X Ray Plasma Sources

Radiation protection dosimetry, 2002-01, Vol.100 (1-4), p.429-432

2002

Volltextzugriff (PDF)

Proton emission from thin hydrogenated targets irradiated by laser pulses at 10(16) W∕cm2

Review of scientific instruments, 2012-02, Vol.83 (2), p.02B315-02B315

2012

Volltextzugriff (PDF)

Some experiences in feeding the aged

Journal of geriatric psychiatry, 1976, Vol.9 (1), p.81

Krasa, E J

1976

Volltextzugriff (PDF)

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

The New England journal of medicine, 2012-12, Vol.367 (25), p.2407-2418

2012

Volltextzugriff (PDF)

Prevalence of autosomal dominant polycystic kidney disease in the European Union

Nephrology, dialysis, transplantation, 2017-08, Vol.32 (8), p.1356-1363

2017

Volltextzugriff (PDF)

Clinical Course of Patients With Hyponatremia and Decompensated Systolic Heart Failure and the Effect of Vasopressin Receptor Antagonism With Tolvaptan

Journal of cardiac failure, 2013-06, Vol.19 (6), p.390-397

2013

Volltextzugriff (PDF)

Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study

American journal of kidney diseases, 2011-05, Vol.57 (5), p.692-699

2011

Volltextzugriff (PDF)

Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience

Clinical journal of the American Society of Nephrology, 2011-10, Vol.6 (10), p.2499-2507

2011

Volltextzugriff (PDF)

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function

American journal of kidney diseases, 2015-06, Vol.65 (6), p.833-841

2015

Volltextzugriff (PDF)

Question of rational pharmaco-therapy of pain in dentistry with non-narcotic analgesics

Die Quintessenz, 1987-06, Vol.38 (6), p.1105

Krása, J

1987

Volltextzugriff (PDF)

Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial

Nephrology, dialysis, transplantation, 2016-11, Vol.31 (11), p.1887-1894

2016

Volltextzugriff (PDF)

Development of a Patient-Reported Outcomes Tool to Assess Pain and Discomfort in Autosomal Dominant Polycystic Kidney Disease

Clinical journal of the American Society of Nephrology, 2023-02, Vol.18 (2), p.213-222

2023

Volltextzugriff (PDF)

Effects of tolvaptan on dyspnoea relief from the EVEREST trials

European heart journal, 2009-09, Vol.30 (18), p.2233-2240

2009

Volltextzugriff (PDF)

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease

Kidney international, 2013-12, Vol.84 (6), p.1278-1286

2013

Volltextzugriff (PDF)

Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT)

American journal of kidney diseases, 2016-06, Vol.67 (6), p.893-901

2016

Volltextzugriff (PDF)

Chronic hyponatremia and association with osteoporosis among a large racially/ethnically diverse population

Osteoporosis international, 2019-04, Vol.30 (4), p.853-861

2019

Volltextzugriff (PDF)

Endocrine alterations that underlie endotoxin-induced disruption of the follicular phase in ewes

Biology of reproduction, 2000, Vol.62 (1), p.45-53

2000

Volltextzugriff (PDF)

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease

Nephrology, dialysis, transplantation, 2017-06, Vol.32 (6), p.969-975

2017

Volltextzugriff (PDF)

Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction

JAMA : the journal of the American Medical Association, 2008-06, Vol.299 (22), p.2656

2008

Volltextzugriff (PDF)

Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure

American journal of health-system pharmacy, 2011-02, Vol.68 (4), p.328-333

2011

Volltextzugriff (PDF)

Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive

Physiological research, 2022-12, Vol.71 (6), p.801-810

2022

Volltextzugriff (PDF)

Hypoxia-inducible factors activator, roxadustat, increases pulmonary vascular resistance in rats

Physiological research, 2023-12, Vol.72 (S5), p.S587-S592

2023

Volltextzugriff (PDF)

Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment

Journal of cardiovascular medicine (Hagerstown, Md.), 2012-07, Vol.13 (7), p.415-422

2012

Volltextzugriff (PDF)

Sub‐acute hyponatraemia more than chronic hyponatraemia is associated with serious falls and hip fractures

Internal medicine journal, 2020-09, Vol.50 (9), p.1100-1108

2020

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieApplied Surface Science

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(49)
magazinearticle
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(40)
Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Female
(24)
Male
(22)
Middle Aged
(20)
Adult
(19)
Aged
(12)
Benzazepines - Therapeutic Use
(10)
Urology & Nephrology
(9)
Biological And Medical Sciences
(8)
Adolescent
(7)
Antidiuretic Hormone Receptor Antagonists
(7)
Double-Blind Method
(7)
Mitral Valve - Surgery
(7)
Mitral Valve Stenosis - Surgery
(7)
Polycystic Kidney, Autosomal Dominant - Drug Therapy
(7)
Treatment Outcome
(7)
Aged, 80 And Over
(6)
Animals
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Response of dosemeters in the radiation field generated by a TW-class laser system

Semiconductor and Thermoluminescent Dosimetry of Pulsed Soft X Ray Plasma Sources

Proton emission from thin hydrogenated targets irradiated by laser pulses at 10(16) W∕cm2

Some experiences in feeding the aged

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

Prevalence of autosomal dominant polycystic kidney disease in the European Union

Clinical Course of Patients With Hyponatremia and Decompensated Systolic Heart Failure and the Effect of Vasopressin Receptor Antagonism With Tolvaptan

Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study

Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function

Question of rational pharmaco-therapy of pain in dentistry with non-narcotic analgesics

Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial

Development of a Patient-Reported Outcomes Tool to Assess Pain and Discomfort in Autosomal Dominant Polycystic Kidney Disease

Effects of tolvaptan on dyspnoea relief from the EVEREST trials

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease

Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT)

Chronic hyponatremia and association with osteoporosis among a large racially/ethnically diverse population

Endocrine alterations that underlie endotoxin-induced disruption of the follicular phase in ewes

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease

Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction

Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure

Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive

Hypoxia-inducible factors activator, roxadustat, increases pulmonary vascular resistance in rats

Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment

Sub‐acute hyponatraemia more than chronic hyponatraemia is associated with serious falls and hip fractures

Aktive Filter

Suchergebnisse filtern